The efficacy of supportive treatment in IgA nephropathy
Not Applicable
- Conditions
- Health Condition 1: null- Patients with biopsy proven primary IgA nephropathy with proteinuria equal to or more than 1g/day and eGFR more than 30ml/min/1.73m2
- Registration Number
- CTRI/2018/01/011414
- Lead Sponsor
- one
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Biopsy proven primary IgA nephropathy with proteinuria>=1g/day
Exclusion Criteria
1.Lack of informed consent
2.eGFR <30ml/min/1.73m2
3.Presence of crescents on kidney biopsy
4.History of immunosuppressive therapy in last 6 months for more than 2 weeks
5. Past history of use of Angiotensin converting enzyme inhibitors(ACEi) or Angiotensin receptor blockers(ARBS) in the previous 6 months
5.Patients with a second coexisting disease on kidney biopsy like diabetic nephropathy
6.Secondary causes of IgA nephropathy like chronic liver disease, Henoch Schonlein Purpura
7.Patient who is pregnant or breast feeding at the time of recruitment
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Achieving complete or partial remission: <br/ ><br>Complete remission: Proteinuria les than 0.5g/day with no greater than 25% decline in eGFR. <br/ ><br>Partial remission:Atleast 50% decline in proteinuria from the baseline with no greater than 25% decline in eGFR <br/ ><br>No response: Less than 50% reduction, unchanged/increasing 24 hour proteinuria from baseline and/or 50% or more decline in eGFR or progression to end stage renal disease which cannot be attributed to any other cause. <br/ ><br>Timepoint: Patients will be followed up monthly for 6months. Those who achieve the primary outcome will be then followed up till 5 years to look for sustained response
- Secondary Outcome Measures
Name Time Method Renal deterioration:50% or more decline in eGFR or progression to end stage renal disease which cannot be attributed to any other cause. <br/ ><br>Timepoint: Monthly follow up till 6 months